CoreCivic Q1 revenue rises 25.8% to $614.7 million; raises 2026 EPS guidance
CoreCivic reported first-quarter 2026 net income of $37.9 million, or $0.38 per diluted share, up from $25.1 million, or $0.23, a year earlier, on revenue of $614.7 million. It raised full-year 2026 diluted EPS guidance to $1.51 to $1.61 from $1.49 to $1.59, and said the update includes its April 1, 2026 acquisition of Clinical Solutions Pharmacy, with an initial price of approximately $148.0 million.
Key points
- Q1 2026 revenue was $614.7 million, up 25.8% from the prior year quarter; net income was $37.9 million, up 51.0%.
- Adjusted diluted EPS was $0.40, up 73.9%, excluding $2.4 million of merger and acquisition expenses.
- Full-year 2026 diluted EPS guidance was raised to $1.51 to $1.61; adjusted EBITDA guidance is $453.8 million to $461.8 million, up from $437.0 million to $445.0 million.
- Guidance reflects a recent decrease in nationwide ICE populations, which the company says it believes is temporary.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.